Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $46.83 Average Target Price from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned an average rating of “Buy” from the ten ratings firms that are covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $52.14.

A number of analysts recently commented on DNTH shares. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating for the company. Finally, Guggenheim restated a “buy” rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. FMR LLC increased its holdings in shares of Dianthus Therapeutics by 0.8% in the 4th quarter. FMR LLC now owns 4,439,281 shares of the company’s stock valued at $96,776,000 after purchasing an additional 36,133 shares during the period. Octagon Capital Advisors LP increased its stake in Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after buying an additional 363,500 shares during the period. TCG Crossover Management LLC acquired a new position in Dianthus Therapeutics in the 4th quarter valued at approximately $32,735,000. Braidwell LP increased its stake in Dianthus Therapeutics by 144.4% in the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock valued at $26,304,000 after buying an additional 712,902 shares during the period. Finally, Alliancebernstein L.P. increased its stake in Dianthus Therapeutics by 13.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock valued at $25,283,000 after buying an additional 136,633 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

DNTH opened at $20.74 on Wednesday. Dianthus Therapeutics has a one year low of $18.13 and a one year high of $33.77. The stock’s fifty day moving average is $22.34 and its 200-day moving average is $24.70. The company has a market capitalization of $613.84 million, a PE ratio of -8.30 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. On average, equities research analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.